Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enhanced efficacy of photodynamic therapy with 3.75% imiquimod in actinic keratosis
2013-004228-12Phase 4Terminated
- Sponsor
- Medical University of Vienna, Department of Dermatology
- Start
- Sep 2014
- Modality
- Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of imiquimod and 5-aminolevulinic acid in actinic keratosis (AK) and cutaneous malignancy (2 arms), sponsored by Medical University of Vienna, Department of Dermatology. Primary endpoint: Percentage of actinic keratosis lesions cleared at 3 months. Started Sep 2014; status: terminated.
02
Drugs
imiquimod5-aminolevulinic acid
03
Conditions
actinic keratosis (AK)cutaneous malignancy
Beyond the preview
Go deeper on 2013-004228-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004228-12.